SREBF1 and fatty liver disease: Moreover, other studies administrating chemical activators of SIRT1, resveratrol and SRT1720, or the NAD+ precursor nicotinamide riboside, reduced SREBP1c, FAS, SCD1 gene and protein expression in the liver of mice/rats with HFD-induced hepatic steatosis [2, 6, 65, 76].